CamCog adds iPad trial tech for cognitive safety, abuse potential

Cambridge Cognition has introduced two iPad-based products for use in clinical trials. The first of the products allows investigators in Phase I trials to measure cognitive impairment. The second automates what the administration sites must do to comply with FDA guidance on the abuse potential of investigational drugs. Both products are underpinned by the company's cloud platform. Release

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.